As reported in DarkDaily, GRAIL, a Silicon Valley based venture, is using gene sequencing to identify, in the bloodstream, free-floating genetic material shed by tumors. Now, a well-funded Silicon Valley startup has developed a blood test that it says holds promise for detecting early-stage lung cancer and other cancers.
Though experimental, the screening test—which uses gene sequencing to identify in the bloodstream cancer-signaling genetic material shed by tumors—would be a boon for clinical laboratories and health networks. It also could play a role in advancing precision medicine treatments and drug therapies.
Grail, based in Menlo Park, CA has raised $1.6 billion dollars.